0.377
price down icon5.70%   -0.0228
pre-market  Vorhandelsmarkt:  .38   0.003   +0.80%
loading
Schlusskurs vom Vortag:
$0.3998
Offen:
$0.3953
24-Stunden-Volumen:
660.17K
Relative Volume:
1.09
Marktkapitalisierung:
$22.02M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-123.46M
KGV:
-0.1456
EPS:
-2.59
Netto-Cashflow:
$-104.11M
1W Leistung:
+1.73%
1M Leistung:
-4.56%
6M Leistung:
-24.54%
1J Leistung:
-77.95%
1-Tages-Spanne:
Value
$0.3718
$0.415
1-Wochen-Bereich:
Value
$0.3254
$0.415
52-Wochen-Spanne:
Value
$0.2601
$2.525

Bioatla Inc Stock (BCAB) Company Profile

Name
Firmenname
Bioatla Inc
Name
Telefon
858-558-0708
Name
Adresse
11085 TORREYANA ROAD, SAN DIEGO
Name
Mitarbeiter
61
Name
Twitter
Name
Nächster Verdiensttermin
2025-03-21
Name
Neueste SEC-Einreichungen
Name
BCAB's Discussions on Twitter

Vergleichen Sie BCAB mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Biotechnology icon
BCAB
Bioatla Inc
0.377 19.94M 0 -123.46M -104.11M -2.59
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
472.27 120.73B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
564.64 61.80B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
328.00 42.46B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
591.74 35.22B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
296.46 31.99B 3.81B -644.79M -669.77M -6.24

Bioatla Inc Stock (BCAB) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2024-11-13 Herabstufung H.C. Wainwright Buy → Neutral
2022-09-15 Eingeleitet JMP Securities Mkt Outperform
2022-05-05 Herabstufung Credit Suisse Outperform → Neutral
2022-03-21 Eingeleitet H.C. Wainwright Buy
2021-10-15 Fortgesetzt BTIG Research Buy
2021-06-28 Eingeleitet ROTH Capital Buy
2021-05-05 Fortgesetzt Credit Suisse Outperform
2021-04-26 Fortgesetzt Credit Suisse Outperform
2021-01-11 Eingeleitet BTIG Research Buy
2021-01-11 Eingeleitet Credit Suisse Outperform
2021-01-11 Eingeleitet JP Morgan Overweight
2021-01-11 Eingeleitet Jefferies Buy
Alle ansehen

Bioatla Inc Aktie (BCAB) Neueste Nachrichten

pulisher
Jul 24, 2025

What analysts say about BioAtla Inc. stockConsistently high returns - Autocar Professional

Jul 24, 2025
pulisher
Jul 22, 2025

What drives BioAtla Inc. stock priceFree Stock Index Interpretation - jammulinksnews.com

Jul 22, 2025
pulisher
Jul 22, 2025

BioAtla Inc. Stock Analysis and ForecastFree Stock Index Interpretation - jammulinksnews.com

Jul 22, 2025
pulisher
Jul 22, 2025

Is Now The Time To Buy BioAtla Inc (NASDAQ: BCAB) Stock? - Stocksregister

Jul 22, 2025
pulisher
Jul 22, 2025

Is BioAtla Inc. a good long term investmentHigh-yield market plays - jammulinksnews.com

Jul 22, 2025
pulisher
Jul 22, 2025

Is BioAtla Inc. stock a good hedge against inflationFree Consultation - Newser

Jul 22, 2025
pulisher
Jul 19, 2025

What analysts say about BioAtla Inc. stock outlookFast Gains With Reduced Risk - beatles.ru

Jul 19, 2025
pulisher
Jul 17, 2025

BioAtla Announces Upcoming Oral Presentation at the 2025 European Society for Medical Oncology (ESMO) TAT Asia Meeting - The Manila Times

Jul 17, 2025
pulisher
Jul 15, 2025

What makes BioAtla Inc. stock price move sharplyTrending Stock Alert - Newser

Jul 15, 2025
pulisher
Jul 15, 2025

Why BioAtla Inc. stock attracts strong analyst attentionStable Stocks With High Yield - Newser

Jul 15, 2025
pulisher
Jul 15, 2025

How BioAtla Inc. stock performs during market volatilityPortfolio Boosting Stock Alerts - Newser

Jul 15, 2025
pulisher
Jul 08, 2025

BioAtla (NASDAQ:BCAB) Stock Price Up 2.6% – Here’s Why - Defense World

Jul 08, 2025
pulisher
Jul 04, 2025

BioAtla presents Phase I data of BA3182 for metastatic adenocarcinoma - Yahoo Finance

Jul 04, 2025
pulisher
Jun 20, 2025

BioAtla Approves 2025 Corporate Bonus Plan - TipRanks

Jun 20, 2025
pulisher
Jun 14, 2025

BioAtla, Inc. (NASDAQ:BCAB) Shares Purchased by Two Sigma Investments LP - Defense World

Jun 14, 2025
pulisher
Jun 09, 2025

Jane Street Group LLC Purchases 100,204 Shares of BioAtla, Inc. (NASDAQ:BCAB) - Defense World

Jun 09, 2025
pulisher
Jun 09, 2025

BioAtla, Inc. (NASDAQ:BCAB) Stock Position Lowered by Two Sigma Advisers LP - Defense World

Jun 09, 2025
pulisher
Jun 08, 2025

Millennium Management LLC Cuts Stock Position in BioAtla, Inc. (NASDAQ:BCAB) - Defense World

Jun 08, 2025
pulisher
Jun 07, 2025

BioAtla (NASDAQ:BCAB) Upgraded by Wall Street Zen to Hold Rating - Defense World

Jun 07, 2025
pulisher
Jun 06, 2025

BioAtla presents Phase 2 Oz-V clinical trial data at ASCO 2025 - MSN

Jun 06, 2025
pulisher
Jun 03, 2025

Why Did BioAtla Inc (NASDAQ: BCAB) Drop So Much? - Stocksregister

Jun 03, 2025
pulisher
Jun 03, 2025

BioAtla reports promising trial results for cancer drug By Investing.com - Investing.com South Africa

Jun 03, 2025
pulisher
Jun 02, 2025

BioAtla reports promising trial results for cancer drug - Investing.com

Jun 02, 2025
pulisher
Jun 02, 2025

BioAtla (BCAB) Showcases Promising Data for Ozuriftamab Vedotin in Key Cancer Trial | BCAB Stock News - GuruFocus

Jun 02, 2025
pulisher
Jun 02, 2025

BioAtla Presents Phase 2 Ozuriftamab Vedotin (Oz-V) Clinical Trial Data Demonstrating Compelling Antitumor Activity in HPV-Associated Oropharyngeal Squamous Cell Carcinoma (HPV+ OPSCC) at the 1.8 mg/kg Q2W dosing regimen - The Manila Times

Jun 02, 2025
pulisher
Jun 02, 2025

BioAtla's New Cancer Drug Achieves 13x Better Response Rate Than Standard Treatment in Phase 2 Trial - Stock Titan

Jun 02, 2025

Finanzdaten der Bioatla Inc-Aktie (BCAB)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading
$23.63
price up icon 3.32%
$36.59
price up icon 1.61%
$103.52
price up icon 0.08%
$27.57
price down icon 1.57%
$114.57
price down icon 0.03%
biotechnology ONC
$296.46
price up icon 0.55%
Kapitalisierung:     |  Volumen (24h):